Loading...

CING CINGULATE INC US FDA Inspections 8-K Filing

CNGL

CNG

CINGULATE INC

(CING)

2025 8-K

Financial Results Update

Debt Agreement Announced

FDA Review Acceptance

Stockholder Meeting

Equity Securities Issued

Management Changes

Quarterly Financial Results

Management Changes

New Product Launches

Equity Offerings

Equity Offerings

Divestment of Assets

Financial Statements

Grant Agreement

Financial Results

CEO Allegation Dismissed

Management Changes

FDA Study Completion

Note Purchase Agreement

Financial Results

Stock Offering Increase

Management Changes

Nasdaq Compliance

Share Offering Increase

Stockholder Meeting

Share Offering Update

Financial Results

Delisting Exception Granted

Special Meeting of Stockhol...

Entry Into a Material Defin...

Annual Meeting Approval

Compliance Regained

Financial Results and Update

Financial Results Announcement

Notice of Delisting

Appointment of Directors

Securities Purchase Agreement

Note Conversion Agreement a...

Departure of Directors and ...

Resignation of Director

Reverse Stock Split

Delisting Notice

Financial Results Announcement

Special Meeting of Stockhol...

Equity Investment

Delisting Notice

Other Special Situation

Annual Meeting Results

Promissory Note Amendment

Increase in Offering Price

Transfer of Manufacturing P...

Purchase Agreement and Regi...

Banking Relationship Confir...

Financial Results Announcement

Resignation and Investor Pr...

Agreement for Stock Offering

External Links:

On March 4, 2025, Cingulate Inc. announced positive safety results from Phase 3 trials for its ADHD treatment CTx-1301, with no serious adverse events reported. The company has 3,647,655 shares outstanding and expects to submit a final analysis to the FDA by mid-2025.

AI Assistant

CINGULATE INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.